MARKET

KNSA

KNSA

Kiniksa Pharmaceuticals, Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.51
-0.66
-3.44%
Opening 10:31 02/24 EST
OPEN
18.40
PREV CLOSE
19.17
HIGH
18.69
LOW
17.76
VOLUME
33.69K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
5.01
MARKET CAP
869.29M
P/E (TTM)
-5.5981
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KNSA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KNSA stock price target is 27.50 with a high estimate of 35.00 and a low estimate of 22.00.

EPS

KNSA News

More
  • Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
  • Zacks · 02/11 14:12
  • 3 Top Biotech Stocks to Buy in February
  • MotleyFool.com · 02/09 13:29
  • Kiniksa Pharmaceuticals Executive Vice President And Chief Financial Officer, Chris Heberlig To Transition To A Consulting Role Within Co.
  • Benzinga · 02/05 21:40
  • Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
  • Zacks · 02/05 14:21

Industry

Biotechnology & Medical Research
-2.19%
Pharmaceuticals & Medical Research
-2.11%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About KNSA

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.
More

Webull offers kinds of Kiniksa Pharmaceuticals Ltd stock information, including NASDAQ:KNSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNSA stock news, and many more online research tools to help you make informed decisions.